Compare SPRU & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRU | SCLX |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | 4 | 34 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.2M | 48.5M |
| IPO Year | 2019 | N/A |
| Metric | SPRU | SCLX |
|---|---|---|
| Price | $2.91 | $8.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.5K | ★ 107.8K |
| Earning Date | 05-13-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $23,194,000.00 | N/A |
| Revenue This Year | N/A | $122.52 |
| Revenue Next Year | N/A | $186.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 48.68 | N/A |
| 52 Week Low | $1.13 | $4.20 |
| 52 Week High | $6.75 | $34.27 |
| Indicator | SPRU | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 37.35 | 64.08 |
| Support Level | $2.56 | $7.73 |
| Resistance Level | $3.32 | $9.00 |
| Average True Range (ATR) | 0.23 | 0.75 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 27.20 | 79.21 |
Spruce Power Holding Corp is an owner and operator of distributed solar energy assets across the United States (the U.S.), offering subscription-based services to home solar assets and customer contracts, making renewable energy more accessible to everyone. The Company's customers are homeowners and the Company's core solar service offerings generate revenues through, the sale of electricity generated by its home solar energy systems to homeowners, third-party contracts to sell solar renewable energy credits (SRECs) generated by the solar energy systems for fixed prices and the servicing of those agreements for other institutional owners of home solar energy systems.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.